文献速递外周动脉疾病

西罗莫司涂层球囊治疗股腘动脉狭窄闭塞性疾病:疗效、安全性与1年结果——全 comers 登记研究

Sirolimus-Coated Balloon in Femoropopliteal Steno-Occlusive Disease: Efficacy, Safety, and 1-Year Outcomes. An All-Comers Registry.
PubMed 文献 · J Endovasc Ther · 2023-12-12

本研究在单中心连续纳入80例股腘动脉狭窄闭塞病变患者,评估新型西罗莫司涂层球囊的疗效与安全性。1年时主要通畅率为86.3%,免于临床驱动靶病变血运重建率为96.2%,30天和12个月主要安全终点分别为98.7%和97.5%。作者认为该球囊是安全有效的治疗选择,但需长期随访和随机对照试验证实。

要点

  • 1年主要通畅率86.3%,免于临床驱动靶病变血运重建率96.2%。
  • 30天和12个月主要安全终点分别为98.7%和97.5%。

核心结论

  • 作者认为新型西罗莫司涂层球囊是治疗股腘动脉狭窄闭塞病变的安全有效选择,但结果需长期随访和随机对照试验证实。

研究设计与样本

  • 本研究为单中心全 comers 登记研究,2021年2月至2022年3月连续纳入80例股浅动脉狭窄闭塞病变患者(年龄69.5±8.23岁,病变80处)。
  • 60例(75%)患者有间歇性跛行,20例(25%)有慢性肢体威胁性缺血(CLTI);平均病变长度171±82.22 mm。

主要发现

  • 器械成功在全部80例患者中实现;1例患者于第7天死于心血管并发症,因发生在出院后30天内被判定为手术相关。
  • 2例CLTI患者按计划行靶肢体小截肢,1例患者因术后60天早期闭塞行靶血管紧急旁路移植术。
  • 主要安全终点在30天和12个月分别为98.7%和97.5%;1年主要通畅率为86.3%,免于CD-TLR率为96.2%。

关键数值与推荐

  • 主要疗效终点为12个月主要通畅率,定义为双功超声收缩期峰值流速比≤2.4且无再狭窄。
  • 次要疗效终点为12个月免于临床驱动靶病变血运重建(CD-TLR)。
  • 主要安全终点为30天和12个月免于器械及手术相关死亡、靶肢体大截肢和临床驱动靶病变紧急血运重建(腔内或旁路移植)的复合终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出结果需长期随访和随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess the efficacy and safety of the novel SLR (SELUTION sustained-limus-release) drug-coated balloon (DCB) in the treatment of the femoropopliteal steno-occlusive disease. MATERIALS AND METHODS: From February 2021 to March 2022, 80 consecutive patients (age: 69.5±8.23 years; total number of lesions: 80) with a steno-occlusive lesion of superficial femoral artery were enrolled at our center. A total of 60 patients (75%) had claudication, whereas 20 (25%) had chronic limb-threatening ischemia (CLTI). The mean lesion length was 171±82.22 mm. The primary efficacy outcome was primary patency at 12 months, defined as freedom from restenosis determined by a duplex ultrasound peak systolic velocity ratio ≤2.4. The secondary efficacy outcome was freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months. The primary safety outcome was a composite of freedom from device- and procedure-related mortality, major target limb amputation, and clinically-driven target lesion urgent revascularization (endovascular or bypass graft) at 30 days and 12 months. RESULTS: Device success was achieved in all 80 patients. One death on day 7 from cardiovascular complications was ruled procedure-related because it occurred within the first 30 days from the discharge. Two patients with CLTI experienced planned minor amputations of target limb, and one patient underwent urgent bypass graft of the target vessel for early occlusion at 60 days from the index procedure. The primary safety outcome was 98.7% and 97.5% at 30 days and 12 months, respectively. At 1 year, primary patency was 86.3%, and freedom from CD-TLR was 96.2%. CONCLUSION: These findings suggest that using a novel sirolimus-coated balloon is a safe and effective treatment option for femoropopliteal steno-occlusive lesions in a variety of clinical and anatomical settings. These results will need to be confirmed by long-term follow-up and randomized controlled trials.Clinical ImpactIn femoropopliteal steno-occlusive lesions paclitaxel drug-coated devices have been proved to be able to achieve a better vessel patency during follow-up compared with uncoated balloon, but according to a recent meta-analysis they may carry an elevated risk of late mortality. Sirolimus results in a wider therapeutic range with a 3-fold higher margin of safety. Sirolimus coated devices have recently been proposed as an alternative. This study suggests that using a novel sirolimus-coated balloon is a safe and effective treatment option for femoropopliteal steno-occlusive lesions.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Franzese M, Pucciarelli A, Spione F, et al. Sirolimus-Coated Balloon in Femoropopliteal Steno-Occlusive Disease: Efficacy, Safety, and 1-Year Outcomes. An All-Comers Registry. J Endovasc Ther. 2023. PMID: 38084379. doi:10.1177/15266028231217657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。